PROMETHEUS Anser IFX
Test Catalog Information
| Test Catalog Synonyms | |
| EPIC Synonyms | |
| Cerner Primary Mnemonic | PROMETHEUS Anser IFX |
| EPIC Display Name | PROMETHEUS Anser IFX |
| Allscripts (AEHR) Order Name | Prometheus Anser IFX |
| Sunrise Clinical Manager (SCM) Order Name | PROMETHEUS Anser IFX |
| EPIC Inpatient Orderable | No |
| EPIC Outpatient Orderable | Yes |
| Cerner Results |
Prometheus Laboratory Footer Serum infliximab (IFX) concentration Antibodies to infliximab concentration PROMETHEUS Anser IFX |
| Clinical Info |
This test is being discontinued Please order INFLIXIMAB Serum concentrations of IFX may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of IFX have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to IFX by producing antibodies to Infliximab (ATI). The presence of ATI has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of IFX and ATI levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response. The PROMETHEUS Anser VDZ test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum VDZ and ATV levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action. |
| Specimen Type |
Blood |
| Container |
Gold Top Tube |
| Collection Instructions |
Container/Tube: Gold top tube Specimen: 2 mL serum (0.5 ml min) Transport Temperature: Room Temperature Stability: 7 days Room Temperature 7 Days Refrigerated |
| Transport Instructions |
Room Temperature |
| Specimen Stability |
7 days Room Temperature 7 Days Refrigerated |
| Methodology |
Electrochemiluminescence Immunoassay (ECLIA) Test Includes: Serum Infliximab concentration (IFX) and Antibodies to Infliximab (IFX) |
| Days Performed |
Monday - Friday TAT = 4 days from receipt at Prometheus Lab |
| Performing Laboratory |
Prometheus Therapeutics & Diagnostics |
| CPT |
80145 82542 |
| PDM |
1759071 |
Desired Epic Build PROMETHEUS Anser IFX
| Cerner Primary Mnemonic: | PROMETHEUS Anser IFX | |||||||||||||||
| PDM | 1759071 | |||||||||||||||
| Informatics - Workgroup | Immunology | |||||||||||||||
| Synonyms * | ||||||||||||||||
| Display Name * | PROMETHEUS Anser IFX | |||||||||||||||
| Order Entry Specimen Sources * | ||||||||||||||||
| Order Entry Specimen Types | ||||||||||||||||
| Specimen Navigator Specimen Types | ||||||||||||||||
| Specimen Navigator Specimen Sources | ||||||||||||||||
| Specimen Navigator Short Name | ||||||||||||||||
| Ordering info (EPIC SmartText) | This test is being discontinued Please order INFLIXIMAB Serum concentrations of IFX may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of IFX have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to IFX by producing antibodies to Infliximab (ATI). The presence of ATI has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of IFX and ATI levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response. The PROMETHEUS Anser VDZ test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum VDZ and ATV levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action. | |||||||||||||||
| IP Orderable | No | |||||||||||||||
| OP Orderable | Yes | |||||||||||||||
|
AOEs * | ||||||||||||||||
| AP AOEs | ||||||||||||||||
| Special History | No | |||||||||||||||
| Build Comments | Do not build | |||||||||||||||
| Filter * | ||||||||||||||||
| Procedure Category Change | ||||||||||||||||
Cerner Results
| ||||||||||||||||
Current Actual EPIC Build as of 10/28/2024
| Procedure Id | 114094 | ||||||||||||||||||||||||||||||
| Pdm | 1759071 | ||||||||||||||||||||||||||||||
| Order Display Name | PROMETHEUS Anser IFX | ||||||||||||||||||||||||||||||
| Procedure Name | PROMETHEUS ANSER IFX | ||||||||||||||||||||||||||||||
| Procedure Master Number | LAB10779 | ||||||||||||||||||||||||||||||
| Short Procedure Name | PROMETHEUS ANSER IFX | ||||||||||||||||||||||||||||||
| Category Code | 1.0 | ||||||||||||||||||||||||||||||
| Category Code Record Name | LAB BLOOD ORDERABLES | ||||||||||||||||||||||||||||||
| Synonyms | |||||||||||||||||||||||||||||||
| Clinically Active | No | ||||||||||||||||||||||||||||||
| Orderable | No | ||||||||||||||||||||||||||||||
| Performable | No | ||||||||||||||||||||||||||||||
| Filter Genomics | |||||||||||||||||||||||||||||||
| Reference Link Url | https://labs.northwell.edu/epic/test/114094 | ||||||||||||||||||||||||||||||
| Ordering Instructions | |||||||||||||||||||||||||||||||
| Default Specimen Type | Blood | ||||||||||||||||||||||||||||||
| Specimen Type Pick List | Blood | ||||||||||||||||||||||||||||||
| Specimen Type List | |||||||||||||||||||||||||||||||
| Op Specimen Type List | |||||||||||||||||||||||||||||||
| Specimen Source Pick List | Blood, Venous Blood, Central Line Blood, Arterial Blood, Capillary | ||||||||||||||||||||||||||||||
| Specimen Source Default - Male | Blood, Venous | ||||||||||||||||||||||||||||||
| Specimen Source Default - Female | Blood, Venous | ||||||||||||||||||||||||||||||
| Specimen Source List | |||||||||||||||||||||||||||||||
| Op Specimen Source List | |||||||||||||||||||||||||||||||
| Ip Lab Test Components For Report | |||||||||||||||||||||||||||||||
| Op Lab Test Components For Report | |||||||||||||||||||||||||||||||
| Order Questions | ["3045300170", "3045300171", "3045300173"] | ||||||||||||||||||||||||||||||
| Order Questions Record Name | NH IP HOME COLLECT DATE NH IP HOME COLLECT DAYS NH IP HOME COLLECT MEDICALLY NECESSARY | ||||||||||||||||||||||||||||||
| Inpatient Order Questions | [] | ||||||||||||||||||||||||||||||
| Inpatient Order Questions Record Name | |||||||||||||||||||||||||||||||
| Order Specific Question Override | Yes | ||||||||||||||||||||||||||||||
| Inpatient Question Override | |||||||||||||||||||||||||||||||
| Location Restrict List Ip | |||||||||||||||||||||||||||||||
| Location Restrict List Ip Record Name | |||||||||||||||||||||||||||||||
| Location Restrict List Include Ip | |||||||||||||||||||||||||||||||
| Location Restrict List Op | |||||||||||||||||||||||||||||||
| Location Restrict List Op Record Name | |||||||||||||||||||||||||||||||
| Location Restrict List Includes Op | |||||||||||||||||||||||||||||||
| Edp Amb Order Specific Questions Record Name | |||||||||||||||||||||||||||||||
| Edp Ip Order Specific Questions Record Name | |||||||||||||||||||||||||||||||
| Edp Ip Specimen Source | Blood, Venous Blood, Central Line Blood, Arterial Blood, Capillary | ||||||||||||||||||||||||||||||
| Edp Op Specimen Source | |||||||||||||||||||||||||||||||
| Edp Ip Specimen Type | Blood | ||||||||||||||||||||||||||||||
| Edp Op Specimen Type | |||||||||||||||||||||||||||||||
| Derived Edp Ip Buttons S | Blood, Central Line Blood, Venous Blood, Capillary Blood, Arterial | ||||||||||||||||||||||||||||||
| Derived Edp Ip Buttons T | Blood | ||||||||||||||||||||||||||||||
| Derived Edp Op Buttons S | |||||||||||||||||||||||||||||||
| Derived Edp Op Buttons T | |||||||||||||||||||||||||||||||
| Ip Orderable | 0 | ||||||||||||||||||||||||||||||
| Op Orderable | 0 | ||||||||||||||||||||||||||||||
EPIC OP AOEs
| |||||||||||||||||||||||||||||||
| EPIC IP AOEs | |||||||||||||||||||||||||||||||
EPIC Components (results)
| |||||||||||||||||||||||||||||||